Search Results

Shanghai Kehua Bio-engineering Co., Ltd, China’s leading In Vitro Diagnostic company has achieved a significant milestone by becoming the first Chinese company to obtain EU Class D In Vitro Diagnostic Regulation certification for rapid tests.

Changchun GeneScience Pharmaceutical, a subsidiary of Changchun High-Tech Industries, held a groundbreaking ceremony for its new global headquarters and research & development center at Shanghai Zhangjiang International Medical Park on December 15th.

Shanghai Argo Biopharmaceutical Co., Ltd. announced that it has entered into two exclusive license and collaboration agreements with Novartis PHARMA AG.

Akoya Biosciences, Inc., The Spatial Biology Company®, and Shanghai KR Pharmtech have jointly announced that KR-HT5, which Akoya Biosciences co-developed with Shanghai KR Pharmtech utilizing the PhenoImager HT technology as its foundation, has received premarket approval from China’s National Medical Products Administration to support next generation pathology clinical workflows.

MDimune Inc. announced today that it took up residence at Johnson & Johnson Innovation – JLABS @ Shanghai (‘JLABS’), located in Shanghai, China, starting in September.

A day after inking an AI deal with Alphabet’s Isomorphic Labs, Novartis is back at it, acquiring Calypso Biotech and tying up with Shanghai Argo in two RNA-i-focused pacts.

Recently has unveiled a remarkable announcement: the inauguration of the Huahai Institute of Vitiligo Research in Shanghai.